聚乙二醇干扰素α-2b联合恩替卡韦治疗慢性乙型病毒性肝炎患者的效果  

Effects of Pegylated interferonα-2b combined with Entecavir in treatment of patients with chronic hepatitis B

作　　者：张明丽 ZHANG Mingli(Department of Hepatology of Fifth People’s Hospital of Anyang,Anyang 455000 Henan,China)

机构地区：[1]安阳市第五人民医院肝病内科,河南安阳455000

出　　处：《中国民康医学》2025年第9期60-62,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察聚乙二醇干扰素α-2b联合恩替卡韦治疗慢性乙型病毒性肝炎(CHB)患者的效果。方法:回顾性分析2020年8月至2023年8月该院收治的60例CHB患者的临床资料,按治疗方案不同将其分为对照组(n=30)与研究组(n=30)。对照组采用恩替卡韦治疗,研究组在对照组基础上采用聚乙二醇干扰素α-2b治疗,比较两组临床疗效,治疗前后肝硬度(LSM)、肝功能指标[天冬氨酸氨基转移酶(AST)、总胆红素(TBIL)、丙氨酸氨基转移酶(ALT)]水平,以及不良反应发生率。结果:研究组治疗总有效率为93.33%(28/30),高于对照组的73.33%(22/30),差异有统计学意义(P<0.05);治疗3、6个月后,两组LSM水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组AST、TBIL、ALT水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:聚乙二醇干扰素α-2b联合恩替卡韦治疗CHB患者可提高治疗总有效率,以及降低肝硬度和肝功能指标水平的效果优于单纯恩替卡韦治疗。Objective:To observe effects of Pegylated interferonα-2b combined with Entecavir in treatment of patients with chronic hepatitis B(CHB).Methods:The clinical data of 60 patients with CHB admitted to this hospital from August 2020 to August 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group(n=30)and study group(n=30).The control group was treated with Entecavir,while the study group was treated with Pegylated interferonα-2b on the basis of that of the control group.The clinical efficacies,the liver stiffness measurement(LSM),the liver function indexes[aspartate aminotransferase(AST),total bilirubin(TBIL),alanine aminotransferase(ALT)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 93.33%(28/30),which was higher than 73.33%(22/30)of the control group,and the difference was statistically significant(P<0.05).After 3 and 6 months of treatment,the levels of LSM in the two groups were lower than those before the treatment,that in the study group was lower than that in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of AST,TBIL and ALT in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Pegylated interferonα-2b combined with Entecavir in the treatment of the CHB patients can improve the total effective rate of treatment,and reduce the levels of liver hardness and liver function indexes.Moreover,it is superior to simple Entecavir treatment.

关 键 词：慢性乙型病毒性肝炎 聚乙二醇干扰素Α-2B 恩替卡韦 肝硬度 肝功能 不良反应 

分 类 号：R511[医药卫生—内科学]